CEL-SCI Corporation (NYSE American: CVM) announced that it will present new data from its Phase 3 study of Multikine (Leukocyte Interleukin Injection) at the European Society for Medical Oncology (ESMO) 2024 Congress, taking place from September 13-17, 2024, in Barcelona, Spain. The presentation, titled “Prognostic Significance of Diagnostic Staging in Treatment-Naïve, Resectable Locally Advanced Primary Oral Cavity Squamous Cell Carcinoma for Neoadjuvant Leukocyte Interleukin Injection Immunotherapy,” will be delivered by co-author József Tímár, MD, PhD, DSc, a renowned pathologist.
CEL-SCI Corporation has received FDA approval to start a confirmatory Registration Study for Multikine in treating head and neck cancer, following promising safety and efficacy results from its Phase 3 IT-MATTERS study.
Dr. József Tímár, a leading pathologist and Director of the Central Pathology Laboratory for the IT-MATTERS study, is a professor at Semmelweis University in Budapest, Hungary. With 174 peer-reviewed publications and significant editorial roles in oncology journals, Dr. Tímár has received numerous accolades for his cancer research and teaching.
About CEL-SCI Corporation
CEL-SCI aims to enhance patient survival by stimulating the immune system before it is compromised. Multikine (Leukocyte Interleukin Injection) is a pioneering first-line cancer therapy that has been administered to over 740 patients. It has received Orphan Drug designation from the FDA for neoadjuvant therapy in head and neck squamous cell carcinoma. Multikine demonstrated a 73% five-year survival rate compared to 45% without the treatment. The FDA has approved CEL-SCI’s patient selection criteria for a focused confirmatory Registration Study, which will involve 212 patients with newly diagnosed, locally advanced primary head and neck cancer, showing no lymph node involvement and low PD-L1 tumor expression. This study targets a global patient population of over 100,000 annually.
CEL-SCI operates in Vienna, Virginia, and near Baltimore, Maryland.
